Stay updated on Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Sign up to get notified when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.

Latest updates to the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page
- ChecktodayChange DetectedUpdated the page from v3.0.1 to v3.0.2, indicating a software release update; removed the 'Back to Top' element as part of the UI cleanup.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated to include information on non-alcoholic fatty liver disease and has been revised to version 3.0.1.SummaryDifference0.3%
- Check15 days agoChange DetectedThe web page has updated its facility name and location details, including the addition of specific drug information for Crizanlizumab and firsocostat, while removing several previous location-related terms and genetic information topics.SummaryDifference2%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check36 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.